Sanofi and Regeneron today noted that their rival PCSK9 inhibitor triggered a significant drop in LDL levels among patients with a high level of the "bad" kind of cholesterol.
As Bloomberg reports, the Pfizer board rewarded CEO Ian Read with a $25 million paycheck.
Pharma's co-pay discounts have their fans--patients, certainly, but they also have their detractors.
Ranbaxy Laboratories launched its version of the cholesterol blockbuster Lipitor in Italy, Sweden and the Netherlands, while its German subsidiary unveiled the Lipitor copy in that country.
Merck's ($MRK) bid to get a combination Zetia- Lipitor cholesterol pill on the market faces a new hurdle. The FDA wants to see more data on the pill. The company hopes ongoing studies will fill...
The FDA's cautionary word on statin use has stirred up a back-and-forth risk-benefits debate. When the agency announced last week that it would highlight the risk of Type 2 diabetes on the cholesterol drugs' labels, some prominent heart doctors issued their own warnings: Don't worry too much about that risk. For most patients, the heart benefits of statins outweigh the "small" risk of developing diabetes.
Big-selling cholesterol drugs got new warnings on their labels, but the cautionary language about blood sugar and memory loss isn't expected to diminish their popularity much.
Lipitor just got shot down by a healthcare plan. As The Wall Street Journal reports, WellPoint ($WLP) is planning to stop covering Pfizer's ($PFE) brand-name cholesterol drug April 1, favoring its
The DTC juggernaut is weakening. As The New York Times reports, industry spending on TV ads fell by 2% in 2011, the fourth consecutive year of decline. Altogether, TV spending is down 20% from 2007...
Pfizer ($PFE) and Eli Lilly ($LLY) are continuing the downward-sloping earnings trend that's dominated Big Pharma's fourth-quarter reports. Pfizer saw profits drop by half, while Lilly's earnings